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Abstract
CCR5 and its ligands play important roles in RA and SLE. A deletion of 32 
basepairs (Δ32 bp) in its gene leads to the production of a non-functional 
receptor. Although a protective effect of CCR5 Δ32 for the development of RA 
has been suggested, future study is required to establish the exact role of this 
deletion for susceptibility to SLE and LN. Also with regard to the association of 
CCR5 Δ32 with disease severity in RA and SLE, more data are needed to draw 
firm conclusions. This might become even more relevant as a CCR5 blocking 
agent is now available.
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Introduction
Chemokines (CC) are a family of proteins playing an important role in 
inflammation since they attract inflammatory cells. CCs are important in 
homeostatic and in inflammatory conditions, and have been found increased 
in several autoimmune diseases. CCs exert their effects by interacting with CC 
receptors (CCR) that are expressed on the surface of inflammatory cells e.g. 
CCR5. CCR5 has several ligands, like CCL5/RANTES, MIP-1α/β, and MCP-2 
and is highly expressed on T cells and is important for their recruitment. 
A deletion of 32 bp (Δ32 bp) in the gene encoding for CCR5 leads to the 
production of an a-functional receptor.
The CCR5 Δ32 bp deletion is predominantly found in Europe (Western Europe 
10%) and Western Asia. It is a relatively recent mutation (700 - 3,500 yrs old) 
that has been quickly distributed throughout Europe, due to a large putative 
fitness advantage (> 10%), e.g. an advantage with regard to smallpox infection. 
Its geographic distribution pattern strongly suggests a Viking origin but origin 
outside of Northern Europe cannot be excluded.1
The clinical importance of CCR5 Δ32 bp deletion has first been demonstrated in 
HIV infection, where CCR5 acts as important co-receptor, leading to an almost 
100% resistance in CCR5 Δ32 homozygosity.2 Later, CCR5 Δ32 bp deletion 
has been reported to (partially) protect against several autoimmune diseases, 
progression of (inflammatory) kidney diseases and on solid organ allograft 
rejection. Here we discuss the role of the CCR5 Δ32 bp deletion in RA and SLE, 
focusing on its role in disease susceptibility and severity. Therapeutic aspects 
of CCR5 blockade will be addressed.
CCR5 Δ32 bp deletion in RA
In RA, CCR5 is important in the pathogenesis of inflammation. An enrichment 
of CCR5 positive monocytes has been demonstrated in the synovial fluid of RA 
patients.3 In synovial tissues, an increased expression of CCL5/RANTES has 
been found in lining layer cells, macrophages, and fibroblasts.4
Whether the CCR5 Δ32 bp deletion is associated with disease susceptibility is 
controversial and some studies could not confirm its protective effect for RA.3;5 
A meta-analysis (5 studies/1790 RA patients) suggested a protective effect of 
CCR5 Δ32 bp deletion on development of RA (pooled odds ratio 0.65; 95 % CI 
0.55-0.77).6
Regarding the role of CCR5 Δ32 in disease severity, also conflicting results 
have been reported. Several studies reported less severe disease (such as less 
swollen joints, less morning stiffness and lower frequency of RF positivity) in 
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RA patients carrying CCR5 Δ32 bp deletion.7;8 These studies are challenged 
by Kohem et al., who found more severe disease in RA patients carrying 
CCR5 Δ32 bp deletion (not statistically significant). The authors stated that 
other proinflammatory mechanisms might overcome the protective role of 
CCR5 Δ32.3 Others did not report any influence of CCR5 Δ32 on the phenotype 
of RA and other pathogenic and proinflammatory factors may play more 
important roles in severity of RA.
CCR5 Δ32 bp deletion in SLE and lupus nephritis
Like in RA, the CC system is also of importance for inflammation in SLE, 
where increased levels of several CCs have been found during active 
disease.9 Again, CCR5 and its ligands are involved in SLE. Compared with 
normal healthy donors, SLE patients have higher serum levels of the CCR5 
ligand RANTES.10 Only few studies have been performed with regard to 
the association of SLE with CCR5 Δ32 bp deletion and the available data 
on SLE suggests an increased risk of SLE.11 Gomez-Reino et al. did not find 
significant differences of CCR5 Δ32 bp deletion between patients with SLE 
and normal healthy donors12, although the frequency of CCR5 Δ32 bp deletion 
homozygosity was higher in SLE patients (0.027) than in normal healthy 
donors (0.009). In conclusion, there is no protective effect of CCR5 Δ32 bp 
deletion in SLE. On the contrary, based on the limited data available for SLE, 
CCR5 Δ32 bp deletion might even be associated with an increased risk.
The difference between RA (protective) and SLE (increased risk) with respect 
to diseases association of CCR5 Δ32 bp deletion is remarkable. It has been 
postulated that differences in the distribution of T-helper (Th) subsets between 
RA and SLE explain this difference in association.12 CCR5 is predominantly 
expressed on Th1 memory/effector cells. In RA, Th1 cells expressing CCR5 
play an important role, where as in SLE, Th2 cells seem to dominate. The ratio 
of CCR5 and CCR3 (preferentially expressed on Th2 cells) expressing T cells 
was higher in peripheral blood of patients with RA, compared to those with 
SLE, where inflammation may be driven by other CCs than CCL5/RANTES. 
In contrast to RA, no specific data regarding CCR5 Δ32 bp deletion and disease 
severity is available for SLE, however, CCR5 Δ32 bp deletion was associated 
with increased titres of anti-dsDNA.13
One of the most severe manifestations of SLE is lupus nephritis (LN), where 
a clear involvement of CCs and CC receptors has been described. In a murine 
lupus model, renal expression of CCL5/RANTES and CCR5, but also of other 
CCs and their receptors, was clearly increased14 and preceded proteinuria and 
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histologic evident renal damage. Involvement of CCR5 has also been found in 
human LN.15 Despite LN being predominantly a glomerular disease, CCR5+ T 
cell infiltration is more prominent in the tubulo-interstitium than in glomeruli. 
In LN, CCL5 / RANTES first is excreted from glomeruli or mesangial cells and 
then absorbed by the tubuli causing recruitment of inflammatory cells into 
the tubulo-interstitial spaces. In contrast to data supporting a role of CCR5 in 
human LN, a more prominent role of CCR4 was observed in another study.16 
No specific data is available with respect to the role of CCR5 Δ32 bp deletion in 
susceptibility for LN.
CCs and their receptors, e.g. CCR5, are important not only for the initiation but 
also for the progression of several kidney diseases.17 CCR5 positive T cells are 
important for progression of inflammation, ultimately leading to fibrosis and 
loss of organ function. There are no data available for the role of CCR5 Δ32 bp 
deletion on the progression of renal disease in SLE. 
CCR5 as target for treatment of RA and SLE
The clinical relevance of CCR5 Δ32 bp deletion has first been discovered 
in HIV infection, and resulted in the development of the CCR5 antagonist 
Maraviroc® for the treatment of infection with CCR5-tropic HIV.18 As CCs and 
their receptors play important roles in autoimmune diseases, they constitute 
an attractive therapeutical target.19 Until now, little data is available on the 
blockage of CCR5 in RA or SLE. In a murine model of apoferritin induced 
glomerulonephritis, administration of RANTES blocking analogs reduced 
glomerular infiltration of leukocytes.20 Surprisingly, glomerular accumulation 
of proinflammatory macrophages with a foam-like appearance, enhanced 
iNOS expression, and decreased uptake of inflammatory cells was observed 
and caused increased albuminuria and renal damage. However, one has to 
take in mind that this experiment was performed in BALB/c mice and not in 
lupus-prone mice. So it remains unclear whether the conclusions of this study 
are applicable to LN.
Although the relevance of CCR5 Δ32 bp deletion in RA and SLE is not 
fully elucidated, CCR5 might still be a therapeutic target in these diseases, 
employing CCR5 antagonists. Results of a phase II clinical trial in RA patients 
comparing treatment with methotrexate combined with Maraviroc® or with 
placebo are expected to be available in 2009 (NCT00427934).
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